Aquestive Therapeutics (NASDAQ:AQST) vs. China SXT Pharmaceuticals (NASDAQ:SXTC) Head-To-Head Review

China SXT Pharmaceuticals (NASDAQ:SXTC) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Institutional & Insider Ownership

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for China SXT Pharmaceuticals and Aquestive Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	0	0	0	0	N/A
Aquestive Therapeutics	0	0	6	1	3.14

Aquestive Therapeutics has a consensus price target of $8.83, indicating a potential upside of 85.77%. Given Aquestive Therapeutics’ higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than China SXT Pharmaceuticals.

Profitability

This table compares China SXT Pharmaceuticals and Aquestive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Aquestive Therapeutics	-44.07%	N/A	-28.26%

Earnings and Valuation

This table compares China SXT Pharmaceuticals and Aquestive Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.93 million	1.06	-$3.10 million	N/A	N/A
Aquestive Therapeutics	$50.58 million	8.56	-$7.87 million	($0.35)	-13.59

China SXT Pharmaceuticals has higher earnings, but lower revenue than Aquestive Therapeutics.

Risk and Volatility

China SXT Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500.

Summary

Aquestive Therapeutics beats China SXT Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.